Consensus EPS · Q2 2026
$2.08
Consensus revenue · Q2 2026
$840M
Analysts
10
Last reported
Jul 23, 2026
Analyst consensus
Based on estimates from 10 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $830M | $840M | $854M |
| EPS | $2.05 | $2.08 | $2.10 |
| EBITDA | $228.9M | $230.1M | $231.9M |
| EBIT | $191.2M | $192.1M | $193.6M |
| Net income | $147M | $148.4M | $149.8M |
- Revenue$840M
- EPS$2.08
- EBITDA$230.1M
- EBIT$192.1M
- Net income$148.4M
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q2 2026 | $872.3M | $840M | +3.8% | $2.37 | $2.08 | +13.9% |
| Q1 2026 | $844.9M | $780.3M | +8.3% | $2.13 | $1.68 | +26.9% |
- Q2 2026+3.8%+13.9%
- Q1 2026+8.3%+26.9%
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
No community consensus
No TickerLeague members predicted West Pharmaceutical Services (WST) Q2 2026 before it reported.
Analyst price target
Based on price targets from 4 analysts.
- Low
- $295.00
- Consensus
- $370.25
- Median
- $377.50
- High
- $447.00
- Current
- $328.20
- Upside
- +12.8%
Upside calculated vs most recent trading price of $328.20.
Analyst ratings
Consensus: Buy — based on 15 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 9, 2026 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Jul 6, 2026 | Evercore ISI Group | maintain | Outperform | Outperform |
| Jul 2, 2026 | Keybanc | maintain | Overweight | Overweight |
| Jun 9, 2026 | Barclays | upgrade | Equal Weight | Overweight |
| Jun 2, 2026 | Stephens & Co. | maintain | Overweight | Overweight |
| May 29, 2026 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Apr 27, 2026 | Barclays | maintain | Equal Weight | Equal Weight |
| Apr 14, 2026 | Barclays | maintain | Equal Weight | Equal Weight |
| Feb 13, 2026 | Barclays | maintain | Equal Weight | Equal Weight |
| Feb 3, 2026 | Evercore ISI Group | maintain | Outperform | Outperform |
- Jul 9, 2026Morgan StanleyEqual Weight
- Jul 6, 2026Evercore ISI GroupOutperform
- Jul 2, 2026KeybancOverweight
- Jun 9, 2026BarclaysOverweight
- Jun 2, 2026Stephens & Co.Overweight
- May 29, 2026Morgan StanleyEqual Weight
- Apr 27, 2026BarclaysEqual Weight
- Apr 14, 2026BarclaysEqual Weight
- Feb 13, 2026BarclaysEqual Weight
- Feb 3, 2026Evercore ISI GroupOutperform
Frequently asked questions
West Pharmaceutical Services (WST) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks2.34% TTM
- Dividend Profile0.27% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History4 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.